Login to Your Account



Simcere’s Evolution

China’s Heavyweight Pharma Goes Private, Expands into Biotech

By Kristine Yang
Contributing Writer

Monday, September 9, 2013

SHANGHAI – When it went public in April 2007, Simcere Pharmaceutical Group quickly became the largest Chinese pharmaceutical listed in the U.S. Despite a good early performance, the stock never lived up to its promise. The firm’s share price crashed to below $5 after the global financial crisis and has been lingering at below $10 since late 2011.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription